Previous PostBioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018
Next PostRelmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms